Integrin αvβ3 is highly expressed in some tumor cells and neovascularization, which is an ideal target for diagnosis and treatment of NSCLC. 177Lu-AB-3PRGD2, is a kind of new drug based on independent research and development in China, provide an effective target for the treatment of NSCLC. All patients underwent whole-body 68Ga-RGD PET/CT for selection and accepted intravenous injection with single dose 1.11 GBq (30 mCi) of 177Lu-AB-3PRGD2 within one week. 1-2 ml venous blood was collected at 30min, 60min, 120min, 1d, 3d, 5d and 7d after administration to detect radioactivity count, respectively. Then monitored at 2, 24, 72, 120 and 168 h after 177Lu-AB-3PRGD2 administration with serial whole body planar and SPECT/CT imaging. Analyze and calculate the internal radiation dose of 177Lu-AB-3PRGD2 and evaluate its therapeutic efficiency and response.
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Non Small Cell Lung Cancerr (NSCLC) who will undergo radioliagnd therapy using 177Lu-AB-3PRGD.